<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082588</url>
  </required_header>
  <id_info>
    <org_study_id>2009-P-002524</org_study_id>
    <secondary_id>09T-1296</secondary_id>
    <nct_id>NCT01082588</nct_id>
    <nct_alias>NCT01363219</nct_alias>
  </id_info>
  <brief_title>Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia</brief_title>
  <official_title>Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Suffolk Mental Health Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves people with schizophrenia or schizoaffective disorder, who are currently
      taking antipsychotic medications. Some antipsychotic medications may cause an increase in
      cholesterol levels, which may lead to inflammation in the body. Inflammation poses a risk in
      developing heart disease, diabetes and problems with brain function. The purpose of this
      study is to see if pravastatin can:

        -  Lower cholesterol

        -  Decrease inflammation

        -  Improve cognition in patients with schizophrenia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week randomized, double-blind, placebo-controlled pilot study of
      pravastatin 40mg a day, administered for 12 consecutive weeks to subjects with schizophrenia
      to examine pravastatin's effects on lowering cholesterol levels and inflammatory markers, and
      improving cognition. The study will be conducted at the Freedom Trail Clinic and will use the
      Massachusetts General Hospital Clinical Research Center. The innovative approach of using
      pravastatin to not only decrease cholesterol levels, but to decrease inflammation and improve
      cognition in patients with schizophrenia is promising and may lead to a different approach to
      treatment in this population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LDL-cholesterol Between Baseline and Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP) From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.
The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorders</condition>
  <condition>Schizophreniform Disorders</condition>
  <arm_group>
    <arm_group_label>pravastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
    <arm_group_label>pravastatin</arm_group_label>
    <other_name>pravastatin sodium</other_name>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18-68 years

          -  Diagnosis of schizophrenia, any subtype, schizoaffective disorder, any subtype or
             schizophreniform disorder

          -  Well established compliance with outpatient medications including their antipsychotic
             medication

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Current substance and alcohol abuse

          -  Significant medical illness, including congestive heart failure, severe cardiovascular
             disease, renal disease (serum creatinine &gt; 1.5), severe hepatic impairment or active
             liver disease, anemia (hemoglobin &lt;11.0 gm/dL), history of severe head injury, and not
             treated muscle disease.

          -  Psychiatrically unstable

          -  Women of child bearing potential who are pregnant, breastfeeding, or who are unwilling
             or unable to use an effective form of birth control during the entire study

          -  Subjects treated with anti-inflammatory drugs (including daily aspirin and ibuprofen),
             thiazide diuretics; agents that induce weight loss, and St. John's Wort will be
             excluded from the study

          -  Current history of untreated thyroid disease

          -  Current treatment with insulin

          -  Subjects being treated with drugs such as: colchicine, azole antifungals (fluconazole,
             ketoconazole, itraconazole); macrolide antibiotics (clarithromycin, erythromycin); HIV
             protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir) that inhibit the
             CYP 450 3A liver enzyme

          -  Known hypersensitivity to pravastatin or any of its components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David C Henderson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Freedom Trail Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci. 2000;917:456-67. Review.</citation>
    <PMID>11268373</PMID>
  </reference>
  <reference>
    <citation>Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F, Kenis G, Bosmans E, de Jongh R, Altamura CA. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res. 2002 Apr 1;54(3):281-91.</citation>
    <PMID>11950553</PMID>
  </reference>
  <reference>
    <citation>Sirota P, Meiman M, Herschko R, Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res. 2005 Apr 15;134(2):151-9.</citation>
    <PMID>15840416</PMID>
  </reference>
  <reference>
    <citation>Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand. 1994 Nov;90(5):311-5.</citation>
    <PMID>7872033</PMID>
  </reference>
  <reference>
    <citation>Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008 Apr 15;63(8):801-8. Epub 2007 Nov 19.</citation>
    <PMID>18005941</PMID>
  </reference>
  <reference>
    <citation>Naudin J, Capo C, Giusano B, Mège JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res. 1997 Aug 29;26(2-3):227-33.</citation>
    <PMID>9323355</PMID>
  </reference>
  <reference>
    <citation>Monteleone P, Fabrazzo M, Tortorella A, Maj M. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. Psychiatry Res. 1997 Jun 16;71(1):11-7.</citation>
    <PMID>9247977</PMID>
  </reference>
  <reference>
    <citation>Boin F, Zanardini R, Pioli R, Altamura CA, Maes M, Gennarelli M. Association between -G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Mol Psychiatry. 2001 Jan;6(1):79-82.</citation>
    <PMID>11244489</PMID>
  </reference>
  <reference>
    <citation>Meira-Lima IV, Pereira AC, Mota GF, Floriano M, Araújo F, Mansur AJ, Krieger JE, Vallada H. Analysis of a polymorphism in the promoter region of the tumor necrosis factor alpha gene in schizophrenia and bipolar disorder: further support for an association with schizophrenia. Mol Psychiatry. 2003 Aug;8(8):718-20.</citation>
    <PMID>12888800</PMID>
  </reference>
  <reference>
    <citation>Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Peña AS. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol. 1996 Apr;43(4):456-63.</citation>
    <PMID>8668926</PMID>
  </reference>
  <reference>
    <citation>Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9.</citation>
    <PMID>9096369</PMID>
  </reference>
  <reference>
    <citation>McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995 Sep;152(9):1291-7.</citation>
    <PMID>7653683</PMID>
  </reference>
  <reference>
    <citation>Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry. 2004 Jul;65(7):940-7.</citation>
    <PMID>15291683</PMID>
  </reference>
  <reference>
    <citation>Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007 Jan 15;149(1-3):267-71. Epub 2006 Nov 16.</citation>
    <PMID>17112596</PMID>
  </reference>
  <reference>
    <citation>Müller N, Riedel M, Scheppach C, Brandstätter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002 Jun;159(6):1029-34.</citation>
    <PMID>12042193</PMID>
  </reference>
  <reference>
    <citation>Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005 Jun 15;57(12):1594-6.</citation>
    <PMID>15953498</PMID>
  </reference>
  <reference>
    <citation>Dziedzic T. Systemic inflammatory markers and risk of dementia. Am J Alzheimers Dis Other Demen. 2006 Aug-Sep;21(4):258-62. Review.</citation>
    <PMID>16948290</PMID>
  </reference>
  <reference>
    <citation>Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol. 2000 Feb 1;103(1):97-102.</citation>
    <PMID>10674995</PMID>
  </reference>
  <reference>
    <citation>Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999 Jul;54(7):M357-64.</citation>
    <PMID>10462168</PMID>
  </reference>
  <reference>
    <citation>Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003 Jul 8;61(1):76-80.</citation>
    <PMID>12847160</PMID>
  </reference>
  <reference>
    <citation>Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology. 2007 May 29;68(22):1902-8.</citation>
    <PMID>17536046</PMID>
  </reference>
  <reference>
    <citation>Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003 Jul 19;327(7407):128. Review.</citation>
    <PMID>12869452</PMID>
  </reference>
  <reference>
    <citation>Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007 Jul;93(1-3):261-5. Epub 2007 May 8.</citation>
    <PMID>17490859</PMID>
  </reference>
  <reference>
    <citation>Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 2009 Dec 1;66(11):1013-22. doi: 10.1016/j.biopsych.2009.06.005. Epub 2009 Jul 29.</citation>
    <PMID>19640511</PMID>
  </reference>
  <reference>
    <citation>Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry. 2000 Jan 1;47(1):8-21. Review.</citation>
    <PMID>10650444</PMID>
  </reference>
  <reference>
    <citation>Tracey KJ. The inflammatory reflex. Nature. 2002 Dec 19-26;420(6917):853-9. Review.</citation>
    <PMID>12490958</PMID>
  </reference>
  <reference>
    <citation>Laflamme N, Rivest S. Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. J Neurochem. 1999 Jul;73(1):309-21.</citation>
    <PMID>10386984</PMID>
  </reference>
  <reference>
    <citation>Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A. Inflammatory response: pathway across the blood-brain barrier. Nature. 2001 Mar 22;410(6827):430-1.</citation>
    <PMID>11260702</PMID>
  </reference>
  <reference>
    <citation>Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007 Feb;7(2):161-7. Epub 2007 Jan 15. Review.</citation>
    <PMID>17220915</PMID>
  </reference>
  <reference>
    <citation>Sjöholm A, Nyström T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006 Jan-Feb;22(1):4-10. Review.</citation>
    <PMID>15991254</PMID>
  </reference>
  <reference>
    <citation>Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91.</citation>
    <PMID>7678183</PMID>
  </reference>
  <reference>
    <citation>Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord. 2004 Aug;5(3):189-97. Review.</citation>
    <PMID>15211090</PMID>
  </reference>
  <reference>
    <citation>Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996 Feb 2;271(5249):665-8.</citation>
    <PMID>8571133</PMID>
  </reference>
  <reference>
    <citation>McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005 Dec 1;80(1):19-32. Epub 2005 Aug 30.</citation>
    <PMID>16137860</PMID>
  </reference>
  <reference>
    <citation>Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004 May 10;164(9):1010-4.</citation>
    <PMID>15136311</PMID>
  </reference>
  <reference>
    <citation>Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4;288(21):2709-16.</citation>
    <PMID>12460094</PMID>
  </reference>
  <reference>
    <citation>Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002 Apr;59(4):337-45. Review.</citation>
    <PMID>11926934</PMID>
  </reference>
  <reference>
    <citation>Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005 Jan;62(1):19-28.</citation>
    <PMID>15630069</PMID>
  </reference>
  <reference>
    <citation>Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998 Oct;47(10):1643-9.</citation>
    <PMID>9753305</PMID>
  </reference>
  <reference>
    <citation>Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H; Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005 Aug;54(8):2404-14.</citation>
    <PMID>16046308</PMID>
  </reference>
  <reference>
    <citation>Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993 Dec 30;329(27):1988-92.</citation>
    <PMID>8247074</PMID>
  </reference>
  <reference>
    <citation>Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest. 2006 Jul;116(7):1813-22. Review.</citation>
    <PMID>16823479</PMID>
  </reference>
  <reference>
    <citation>Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001 Jan;24(1):89-94.</citation>
    <PMID>11194248</PMID>
  </reference>
  <reference>
    <citation>Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005 May;115(5):1111-9. Review.</citation>
    <PMID>15864338</PMID>
  </reference>
  <reference>
    <citation>Nissen SE. Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome? Nat Clin Pract Cardiovasc Med. 2005 Jan;2(1):10-1.</citation>
    <PMID>16265333</PMID>
  </reference>
  <reference>
    <citation>Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005 Jan 6;352(1):29-38.</citation>
    <PMID>15635110</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol &lt;70 mg/dl and C-reactive protein &lt;2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005 May 17;45(10):1644-8. Epub 2005 Apr 25.</citation>
    <PMID>15893181</PMID>
  </reference>
  <reference>
    <citation>Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 Jan;33(1):234-41.</citation>
    <PMID>9935036</PMID>
  </reference>
  <reference>
    <citation>Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):263-9.</citation>
    <PMID>15310527</PMID>
  </reference>
  <reference>
    <citation>Agrawal A. CRP after 2004. Mol Immunol. 2005 May;42(8):927-30. Epub 2004 Dec 7. Review.</citation>
    <PMID>15829284</PMID>
  </reference>
  <reference>
    <citation>Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004 Nov 19;279(47):48487-90. Epub 2004 Aug 26. Review.</citation>
    <PMID>15337754</PMID>
  </reference>
  <reference>
    <citation>Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005 Jan 6;352(1):20-8.</citation>
    <PMID>15635109</PMID>
  </reference>
  <reference>
    <citation>Vuletic S, Riekse RG, Marcovina SM, Peskind ER, Hazzard WR, Albers JJ. Statins of different brain penetrability differentially affect CSF PLTP activity. Dement Geriatr Cogn Disord. 2006;22(5-6):392-8. Epub 2006 Sep 7.</citation>
    <PMID>16960448</PMID>
  </reference>
  <reference>
    <citation>Ventura J, Liberman RP, Green MF, Shaner A, Mintz J. Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I/P). Psychiatry Res. 1998 Jun 15;79(2):163-73.</citation>
    <PMID>9705054</PMID>
  </reference>
  <reference>
    <citation>Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. 1989 Nov;(7):59-67.</citation>
    <PMID>2619982</PMID>
  </reference>
  <reference>
    <citation>Rey JM, Hunt GE, Johnson GF. Assessment of tardive dyskinesia in psychiatric outpatients using a standardized rating scale. Aust N Z J Psychiatry. 1981 Mar;15(1):33-7.</citation>
    <PMID>6973337</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.</citation>
    <PMID>14399272</PMID>
  </reference>
  <reference>
    <citation>Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10(3):388-98.</citation>
    <PMID>6474101</PMID>
  </reference>
  <reference>
    <citation>Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976 Jun;33(6):766-71.</citation>
    <PMID>938196</PMID>
  </reference>
  <reference>
    <citation>Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.</citation>
    <PMID>18172019</PMID>
  </reference>
  <reference>
    <citation>Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, Keefe RS, Mesholam-Gately R, Mintz J, Seidman LJ, Stover E, Marder SR. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am J Psychiatry. 2008 Feb;165(2):214-20. doi: 10.1176/appi.ajp.2007.07010043. Epub 2008 Jan 2.</citation>
    <PMID>18172018</PMID>
  </reference>
  <reference>
    <citation>Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235-45.</citation>
    <PMID>11354591</PMID>
  </reference>
  <reference>
    <citation>Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988 Oct;88(10):1268-71.</citation>
    <PMID>3171020</PMID>
  </reference>
  <reference>
    <citation>McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta. 1987 Jun 30;166(1):1-8.</citation>
    <PMID>3608193</PMID>
  </reference>
  <reference>
    <citation>Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982 Jun;28(6):1379-88.</citation>
    <PMID>7074948</PMID>
  </reference>
  <reference>
    <citation>Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502.</citation>
    <PMID>4337382</PMID>
  </reference>
  <reference>
    <citation>Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48(3-4):171-80. Review.</citation>
    <PMID>11934219</PMID>
  </reference>
  <reference>
    <citation>Levine S. The management of resistant depression. Acta Psychiatr Belg. 1986 Mar-Apr;86(2):141-51.</citation>
    <PMID>3088916</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2010</study_first_submitted>
  <study_first_submitted_qc>March 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2010</study_first_posted>
  <results_first_submitted>November 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2014</results_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David C. Henderson</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>pravastatin</keyword>
  <keyword>inflammation</keyword>
  <keyword>cognition</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All participants were recruited from the Massachusetts General Hospital Schizophrenia Clinical and Research Program.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pravastatin</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pravastatin</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.11" spread="11.06"/>
                    <measurement group_id="B2" value="45.08" spread="12.54"/>
                    <measurement group_id="B3" value="44.84" spread="11.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in LDL-cholesterol Between Baseline and Week 12</title>
        <time_frame>Baseline, week 12</time_frame>
        <population>One participant from the pravastatin group and two from the placebo group had triglyceride levels above 400. Per Massachusetts General Hospital Laboratories policy, LDL is not run as a part of the complete metabolic panel (CMP) when triglycerides are above 400, and therefore could not be included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL-cholesterol Between Baseline and Week 12</title>
          <population>One participant from the pravastatin group and two from the placebo group had triglyceride levels above 400. Per Massachusetts General Hospital Laboratories policy, LDL is not run as a part of the complete metabolic panel (CMP) when triglycerides are above 400, and therefore could not be included in the final analysis.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.565" spread="32.261"/>
                    <measurement group_id="O2" value="-2.913" spread="16.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in C-Reactive Protein (CRP) From Baseline to Week 12</title>
        <time_frame>Baseline, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-Reactive Protein (CRP) From Baseline to Week 12</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8063" spread="5.3515"/>
                    <measurement group_id="O2" value="-0.5136" spread="7.2646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12</title>
        <description>The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.
The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning.</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>One participant from the placebo group refused to complete the MATRICS assessment at week 12; therefore, we could only analyze 24 placebo participants for the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MATRICS Neuropsychological Battery Composite Score From Baseline to Week 12</title>
          <description>The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery measures cognitive functioning within 7 domains: speed of processing, attention/vigilance, working memory (non verbal and verbal), verbal learning, visual learning, reasoning and problem solving and social cognition.
The composite score is calculated by the MATRICS computer program, which equally weights each of the 7 domain scores. The range of composite scores is 20-80. Higher scores indicate higher levels or cognitive functioning, while lower scores indicate lower levels of cognitive functioning.</description>
          <population>One participant from the placebo group refused to complete the MATRICS assessment at week 12; therefore, we could only analyze 24 placebo participants for the final analysis.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0417" spread="5.2789"/>
                    <measurement group_id="O2" value="4.125" spread="6.9739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12</title>
        <description>The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
        <time_frame>Baseline, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 12</title>
          <description>The Positive and Negative Syndrome Scale (PANSS) is a scale used to rate severity of schizophrenia. All items are summed to calculate the total score. The scale range is 30-210. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.416" spread="13.941"/>
                    <measurement group_id="O2" value="-6.48" spread="12.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12</title>
        <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
        <time_frame>Baseline, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) Positive Score From Baseline to Week 12</title>
          <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9583" spread="3.014"/>
                    <measurement group_id="O2" value="-2.44" spread="4.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12</title>
        <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
        <time_frame>Baseline, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) Negative Score From Baseline to Week 12</title>
          <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 7-49. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="5.411"/>
                    <measurement group_id="O2" value="-0.28" spread="3.736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12</title>
        <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
        <time_frame>Baseline, week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pravastatin</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Positive and Negative Syndrome Scale (PANSS) General Score From Baseline to Week 12</title>
          <description>This is a subscale of the Positive and Negative Syndrome Scale (PANSS). The range for this subscale is 15-105. All items are summed to calculate the total score. Better outcomes have lower numbers and worse outcomes have higher numbers.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.625" spread="8.155"/>
                    <measurement group_id="O2" value="-3.76" spread="6.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pravastatin</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Pravastatin: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
Placebo: pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle soreness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Henderson</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-912-7800</phone>
      <email>dchenderson@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

